Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENA-4: AZD9833 plus palbociclib vs anastrozole plus palbociclib in ER-positive HER2-negative advanced breast cancer
jRCT2031210041Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of camizestrant in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival (PFS). Started May 2021; status: active, not recruiting.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031210041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210041.